Dr. Reddy's Laboratories (RDY) Earnings Date, Estimates & Call Transcripts → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free RDY Stock Alerts $74.13 +3.21 (+4.53%) (As of 01:45 PM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryUpcoming Earnings DateMay. 8EstimatedActual EPS (Jan. 31) $0.99 Beat By $0.11 Consensus EPS (Jan. 31) $0.88 Read Call TranscriptListen to Call Get Dr. Reddy's Laboratories Earnings AlertsEnter your email address below to receive the latest news and earnings results for RDY and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueRDY Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.RDY Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. Dr. Reddy's Laboratories Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241$0.71$0.71$0.71Q2 20241$0.88$0.88$0.88Q3 20241$0.87$0.87$0.87Q4 20241$0.86$0.86$0.86FY 20244$3.32$3.32$3.32Q1 20251$1.10$1.10$1.10Q2 20251$0.99$0.99$0.99Q3 20251$1.00$1.00$1.00Q4 20251$1.00$1.00$1.00FY 20254$4.09$4.09$4.09Q1 20261$1.02$1.02$1.02Q2 20261$1.02$1.02$1.02Q3 20261$1.05$1.05$1.05RDY Earnings Date and InformationDr. Reddy's Laboratories last issued its earnings data on January 31st, 2024. The reported $0.99 EPS for the quarter, topping the consensus estimate of $0.88 by $0.11. The company had revenue of $867 million for the quarter, compared to the consensus estimate of $827.81 million. Dr. Reddy's Laboratories has generated $3.79 earnings per share over the last year ($3.79 diluted earnings per share) and currently has a price-to-earnings ratio of 19.6. Earnings for Dr. Reddy's Laboratories are expected to grow by 4.04% in the coming year, from $3.96 to $4.12 per share. Dr. Reddy's Laboratories has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 8th, 2024 based off prior year's report dates.Read More Dr. Reddy's Laboratories Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/8/2024Estimated)------- 1/31/2024Q4 2023$0.88$0.99+$0.11$0.99$827.81 million$867.00 million 10/27/2023Q2 2024$0.88$1.07+$0.19$1.07$825.94 million$832.16 million7/26/2023Q1 2024$0.71$1.03+$0.32$1.03$790.67 million$820.20 million5/10/2023Q4 2023$0.57$0.70+$0.13$0.70$763.37 million$766.00 million1/25/2023Q3 2023$0.60$0.91+$0.31$0.91$769.25 million$818.00 million10/28/2022Q2 2023$0.59$0.82+$0.23$0.82$763.28 million$775.00 million Get the Latest News and Ratings for RDY and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Dr. Reddy's Laboratories and its competitors with MarketBeat's FREE daily newsletter. 7/28/2022Q1 2023$0.58$0.90+$0.32$0.90$767.00 million$660.00 million5/19/2022Q4 2022-$0.53+$0.53$0.99-$717.00 million1/28/2022Q3 2022-$0.57+$0.57$0.57-$715.00 million10/29/2021Q3 2021$0.56$0.80+$0.24$0.80-$777.00 million7/27/2021Q2 2021$0.55$0.46($0.09)$0.46$685.22 million$662.00 million5/13/2021Q1 2021$0.51$0.46($0.05)$0.46-$646.00 million Dr. Reddy's Laboratories Earnings - Frequently Asked Questions When is Dr. Reddy's Laboratories's earnings date? Dr. Reddy's Laboratories has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 8th, 2024 based off last year's report dates. Learn more on RDY's earnings history. Did Dr. Reddy's Laboratories beat their earnings estimates last quarter? In the previous quarter, Dr. Reddy's Laboratories (NYSE:RDY) reported $0.99 earnings per share (EPS) to beat the analysts' consensus estimate of $0.88 by $0.11. Learn more on analysts' earnings estimate vs. RDY's actual earnings. How can I listen to Dr. Reddy's Laboratories's earnings conference call? The conference call for Dr. Reddy's Laboratories's latest earnings report can be listened to online. Listen to Conference Call How can I read Dr. Reddy's Laboratories's conference call transcript? The conference call transcript for Dr. Reddy's Laboratories's latest earnings report can be read online. Read Transcript How much revenue does Dr. Reddy's Laboratories generate each year? Dr. Reddy's Laboratories (NYSE:RDY) has a recorded annual revenue of $2.99 billion. How much profit does Dr. Reddy's Laboratories generate each year? Dr. Reddy's Laboratories (NYSE:RDY) has a recorded net income of $548 million. RDY has generated $3.79 earnings per share over the last four quarters. What is Dr. Reddy's Laboratories's price-to-earnings ratio? Dr. Reddy's Laboratories (NYSE:RDY) has a trailing price-to-earnings ratio of 19.56 and a forward price-to-earnings ratio of 18.72. The price/earnings-to-growth ratio is 1.78. What is Dr. Reddy's Laboratories's EPS forecast for next year? Dr. Reddy's Laboratories's earnings are expected to grow from $3.96 per share to $4.12 per share in the next year, which is a 4.04% increase. More Earnings Resources from MarketBeat Related Companies: Karuna Therapeutics Earnings Date BeiGene Earnings Date Sarepta Therapeutics Earnings Date United Therapeutics Earnings Date Viatris Earnings Date Catalent Earnings Date Teva Pharmaceutical Industries Earnings Date Legend Biotech Earnings Date Ascendis Pharma A/S Earnings Date Intra-Cellular Therapies Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted This page (NYSE:RDY) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThese AI trades triggered this morning (545% return)Prosper Trading AcademyEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsWill this $2 AI stock double overnight?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dr. Reddy's Laboratories Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.